Meeting
2013 ASCO Annual Meeting
GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma.
Authors
Dean Anthony Fennell
University of Leicester, Leicester, United Kingdom
Dean Anthony Fennell , Glenwood D. Goss , Mark A. Socinski , Kazuhiko Nakagawa , Joan H. Schiller , Philip Bonomi , Vera Hirsh , Karen Kelly , James F. Spicer , Rafael Rosell , Bojan Zaric , Tudor-Eliade Ciuleanu , Vojislav M. Vukovic , Florentina Teofilovici , Iman El-Hariry , Wei Guo , Suresh S. Ramalingam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS8126)
DOI
10.1200/jco.2013.31.15_suppl.tps8126
Abstract #
TPS8126
Poster Bd #
43B
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.
First Author: Suresh S. Ramalingam
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2023 ASCO Annual Meeting
Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).
First Author: Anne-Marie C. Dingemans
Poster
2022 ASCO Annual Meeting
Mefatinib as first-line treatment of patients with advanced non–small cell lung cancer harboring rare EGFR mutations.
First Author: Pingli Wang